KN056
Alphamab's GLP-1 / glucagon dual agonist — an early-clinical Chinese entry in the GLP-1/glucagon mechanism space pioneered by cotadutide and now represented by pemvidutide and survodutide.
A dual GLP-1 / glucagon receptor agonist peptide developed by Alphamab (Suzhou), in early clinical development in China for obesity and MASH; occupies the same mechanism space as pemvidutide, survodutide, and the discontinued cotadutide.
Mechanism of action
Balanced agonism at GLP-1 and glucagon receptors — same mechanism class as cotadutide, pemvidutide, and survodutide. The glucagon arm adds thermogenesis / hepatic fat oxidation to standard GLP-1 incretin effects.
Primary uses
- Obesity (early clinical)
- MASH (early clinical)
Typical dosing
Early-clinical doses not publicly finalized.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Regulatory status
Not approved. Early clinical development in China.
Status as of this entry's last review, October 4, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
KN056 is a GLP-1/glucagon dual agonist from Suzhou Alphamab. One paper indexed on PubMed reports its first human trial. This section records what can be checked.
Identity, computed
| Sequence | Not established |
Its structure has not been published in a source we could find, so no formula or mass is given.
Regulatory status, read October 5, 2026
Drugs@FDA: 0 records for “KN056”. EMA medicines list: 0 records for “KN056”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 84 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.
What the maker or sellers claim
Claim, from Alphamab's pipeline: KN056 is a long-acting dual agonist for obesity and metabolic disease. Only phase 1 data have been published.
The one published human study
The single published trial, a randomised, double-blind, placebo-controlled single-dose study in 30 healthy Chinese men, is described in the study card below. Its reported half-life of 141 to 188 hours would suit weekly dosing, but a single dose in healthy men says nothing yet about longer-term weight loss.
What we looked for and did not find
No published multiple-dose or patient trial and no approval anywhere.
| Source | Query | Results, October 5, 2026 | What it was |
|---|---|---|---|
| PubMed | KN056 | 1 | the 2025 phase 1 trial |
| ClinicalTrials.gov | KN056 | 1 | the healthy-participant study |
| Drugs@FDA (openFDA) | KN056 | 0 | |
| EMA medicines list | KN056 | 0 |
What the studies show
KN056 is an injectable candidate from Alphamab studied for type 2 diabetes. Its evidence so far is one phase 1 programme in healthy volunteers.
Registry · 2022
The registered phase 1
Alphamab's phase 1 study in 46 healthy participants tested single subcutaneous doses in ascending cohorts (0.1, 0.3, 1.0 and 3.0 mg are listed); completed in December 2023.
NCT05385575 · ClinicalTrials.gov record
Human · 2025
Single doses in healthy men
In 30 healthy Chinese men given single doses up to 12.0 mg, KN056 lowered glucose in an oral glucose tolerance test by up to 29.9% at 72 hours and reduced weight for about a week (1.68 kg at 12.0 mg) without a lasting change, with pharmacokinetics the authors read as fit for weekly dosing.
References
- [manufacturer] Alphamab pipeline disclosures — KN056 GLP-1/glucagon dual agonist.
- [clinicaltrials] ClinicalTrials.gov NCT05385575: "A Study to Evaluate Effects of KN056 in Healthy Participants" Suzhou Alphamab Co., Ltd.. Phase 1, completed, August 2022 to December 2023 (primary completion), 46 participants. Registry record read October 2, 2026.
- [clinical-trial] Qin YF, et al. "A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants." Expert Opin Investig Drugs, 2025;34(4):329-337. PMID: 40328758.
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.